Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
1.
Biol Pharm Bull ; 46(10): 1461-1467, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37779048

RESUMEN

Since three-dimensional (3D)-printed tablets were approved by the United States Food and Drug Administration (FDA), 3D printing technology has garnered increasing interest for the fabrication of medical and pharmaceutical devices. With various dosing devices being designed for manufacture by 3D printing, 3D-printed ophthalmic formulations to release drugs have been one such target of investigation. In the current study, 3D-printed contact lenses designed for the controlled release of the antibiotic azithromycin were produced by vat photopolymerization, and the effect of the printer ink composition and a second curing process was investigated. The azithromycin-loaded contact lenses were composed of the cross-linking reagent polyethylene glycol diacrylate (PEGDA), PEG 400 as a solvent, a photoinitiator, and azithromycin. The 3D-printed contact lenses were fabricated successfully, and formulations with lower PEGDA concentrations produced thicker lenses. The mechanical strength of the PEGDA-based contact lenses was dependent on the amount of PEGDA and was improved by a second curing process. Drug release from 3D-printed contact lenses was reduced in the samples with a second curing process. The azithromycin-loaded contact lenses exhibited antimicrobial effects in vitro for both Gram-positive and -negative bacteria. These results suggest that 3D-printed contact lenses containing antibiotics are an effective model for treating eye infections by controlling drug release.


Asunto(s)
Azitromicina , Lentes de Contacto , Tecnología Farmacéutica/métodos , Preparaciones de Acción Retardada , Polietilenglicoles , Liberación de Fármacos , Impresión Tridimensional
2.
Biol Pharm Bull ; 44(9): 1309-1315, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34471059

RESUMEN

Confectionery ingredients are expected to enhance the medication adherence of pediatric patients taking bitter-tasting drugs when adequate pediatric medicines are not available in practical settings. Gum is a familiar confectionery, and several drug-loaded gums are on the market as medicated chewing gums. In this study, medical gum tablets composed of confectionery xylitol gum and a drug (ibuprofen or acetaminophen) were prepared and evaluated for the purpose of potential hospital applications. The effect of the sintering process, a heating treatment, on the physical properties of the solid materials was also examined. The sintering process markedly improved the hardness of the gum tablets. The sintering temperature and time affected the hardness of both ibuprofen- and acetaminophen-loaded gum tablets, whereas heat treatment around the melting point of ibuprofen or xylitol and longer heat treatment resulted in failure of the preparation or a reduction in hardness. The sintered gum tablets exhibited a delayed drug release profile in artificial saliva after an in vitro chewing test. The current results provide basic and useful information about the preparation of gum-containing tablets in future clinical settings.


Asunto(s)
Goma de Mascar , Excipientes/química , Cumplimiento de la Medicación , Xilitol/química , Acetaminofén/química , Acetaminofén/farmacocinética , Química Farmacéutica , Niño , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/farmacocinética , Liberación de Fármacos , Humanos , Ibuprofeno/química , Ibuprofeno/farmacocinética , Saliva/química , Comprimidos , Gusto
3.
Mar Drugs ; 18(6)2020 Jun 20.
Artículo en Inglés | MEDLINE | ID: mdl-32575787

RESUMEN

3D printing technology has been applied to various fields and its medical applications are expanding. Here, we fabricated implantable 3D bio-printed hydrogel patches containing a nanomedicine as a future tailored cancer treatment. The patches were prepared using a semi-solid extrusion-type 3D bioprinter, a hydrogel-based printer ink, and UV-LED exposure. We focused on the composition of the printer ink and semi-synthesized fish gelatin methacryloyl (F-GelMA), derived from cold fish gelatin, as the main component. The low viscosity of F-GelMA due to its low melting point was remarkably improved by the addition of carboxymethyl cellulose sodium (CMC), a pharmaceutical excipient. PEGylated liposomal doxorubicin (DOX), as a model nanomedicine, was incorporated into the hydrogel and liposome stability after photo-polymerization was evaluated. The addition of CMC inhibited particle size increase. Three types of 3D-designed patches (cylinder, torus, gridlines) were produced using a 3D bioprinter. Drug release was dependent on the shape of the 3D-printed patches and UV-LED exposure time. The current study provides useful information for the preparation of 3D printed nanomedicine-based objects.


Asunto(s)
Bioimpresión/métodos , Doxorrubicina/análogos & derivados , Sistemas de Liberación de Medicamentos , Proteínas de Peces/química , Gelatina/química , Doxorrubicina/administración & dosificación , Doxorrubicina/farmacocinética , Composición de Medicamentos/métodos , Liberación de Fármacos , Estabilidad de Medicamentos , Humanos , Hidrogeles/química , Luz , Nanopartículas/administración & dosificación , Neoplasias/tratamiento farmacológico , Tamaño de la Partícula , Polietilenglicoles/administración & dosificación , Polietilenglicoles/farmacocinética , Polimerizacion/efectos de la radiación , Impresión Tridimensional , Parche Transdérmico , Viscosidad
4.
Biol Pharm Bull ; 42(10): 1753-1760, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31582663

RESUMEN

The use of three-dimensional (3D) printing technology is expanding in various fields. The application of 3D printing is expected to increase in the pharmaceutical industry after 3D-printed tablets were approved by the U.S. Food and Drug Administration (FDA). Fused deposition modeling (FDM), a type of 3D printing, has been extensively studied for the manufacturing of tablets. A drug-loaded polymer filament, the ink of FDM 3D printers, can be prepared using the hot melt extrusion method or a simple drug-soaking method. In the present study, we investigate the influence of the experimental conditions on the loading of curcumin (model drug with fluorescence) into a polyvinylalcohol polymer filament using the soaking method. We show that organic solvent type (isopropanol, methanol, acetone, and ethanol), temperature (25 and 80°C), and drug concentration (2-333 mg/mL) greatly affect drug loading. Around 5% curcumin can be incorporated into the polyvinylalcohol filament using the soaking method. The drug dissolution from 3D-printed tablets depends on the drug content in the polymer filament. The incorporation of a higher amount of curcumin, which has poor water solubility, greatly delays drug dissolution. These results provide useful information on the preparation of 3D-printed tablets using a drug-loaded polymer filament obtained with the soaking method.


Asunto(s)
Impresión Tridimensional , Comprimidos/química , Tecnología Farmacéutica/métodos , Curcumina/química , Liberación de Fármacos , Alcohol Polivinílico/química , Solubilidad , Solventes/química , Temperatura
5.
Biol Pharm Bull ; 42(11): 1898-1905, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31685772

RESUMEN

Pharmaceutical applications of three dimensional (3D) printing technology are increasing following the approval of 3D-printed tablets by the U.S. Food and Drug Administration. Semi-solid extrusion-type 3D printers are used to 3D print hydrogel- and paste-based materials. We previously developed tablet formulations for semi-solid extrusion-type 3D bioprinters. In the present study, we extended our study to the preparation of muco-adhesive oral film formulations to 3D bioprint mouth ulcer pharmaceuticals. We focused on hydroxypropyl methylcellulose (HPMC)-based catechin (model drug)-loaded hydrogel formulations and found that the viscosity of a hydrogel formulation is dependent on the HPMC concentration, and that viscosity is important for facile 3D printing. HPMC-based films were prepared using two different drying methods (air drying and freeze drying). The films exhibited different drug dissolution profiles, and increasing the amount of HPMC in the film delayed drug dissolution. The fabrication of HPMC-based catechin-loaded films with different shapes provides a model of individualized, on-demand pharmaceuticals. Our results support the flexible application of 3D bioprinters (semi-solid extrusion-type 3D printers) for preparing film formulations.


Asunto(s)
Catequina/uso terapéutico , Composición de Medicamentos/métodos , Metilcelulosa/uso terapéutico , Impresión Tridimensional , Tecnología Farmacéutica/métodos , Adhesivos , Liberación de Fármacos , Derivados de la Hipromelosa , Metilcelulosa/análogos & derivados , Viscosidad
6.
Biol Pharm Bull ; 41(6): 899-907, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29863078

RESUMEN

Microfluidics is a promising system for efficiently optimizing the experimental conditions for preparing nanomedicines, such as self-assembled nanoparticles. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are promising drug carriers allowing sustained drug release. Here, we encapsulated the model drug curcumin, which has many pharmacological activities, into PLGA nanoparticles and investigated the effects of experimental conditions on the resulting PLGA nanoparticles using a microfluidics system with a staggered herringbone structure that can stir solutions through chaotic advection. The total flow rate and flow rate ratio of the solutions in the microfluidics system affected the diameters, polydispersity index, and encapsulation efficiency of the resulting PLGA nanoparticles and produced small, homogenous PLGA nanoparticles. The incorporation of polyethylene glycol (PEG)-PLGA into the PLGA nanoparticles reduced the particle size and improved the encapsulation efficiency. Initial burst release from the PLGA nanoparticles was prevented by the incorporation of PEG2000-PLGA. Curcumin-loaded PEGylated PLGA nanoparticles showed cytotoxicity similar to that of other formulations. This microfluidics system allows high throughput and is scalable for the efficient preparation of PLGA nanoparticles and PEGylated PLGA nanoparticles. Our results will be useful for developing novel PLGA-based polymer nanoparticles by using the microfluidics.


Asunto(s)
Curcumina/química , Composición de Medicamentos/instrumentación , Dispositivos Laboratorio en un Chip , Nanopartículas/química , Poliésteres/química , Polietilenglicoles/química , Células A549 , Supervivencia Celular/efectos de los fármacos , Preparaciones de Acción Retardada/química , Preparaciones de Acción Retardada/toxicidad , Composición de Medicamentos/métodos , Liberación de Fármacos , Humanos , Nanopartículas/toxicidad , Poliésteres/toxicidad , Polietilenglicoles/toxicidad
7.
Biol Pharm Bull ; 41(6): 908-914, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29863079

RESUMEN

Gold nanoparticles (GNPs) have promising properties such as photothermal effects and could be useful for imaging and as multifunctional nanocarriers for various drugs. In this study, we synthesized polyethyleneglycol (PEG)-grafted GNPs and conjugated them with cyclodextrin (CD) to incorporate curcumin. Curcumin has anticancer effects but its therapeutic application is limited due to poor water solubility. Three types of CDs (α-, ß-, and γ-CDs) were conjugated with PEGylated GNPs and the curcumin-containing CD/PEG-conjugated GNPs (cur-CD-GNPs) were characterized. Transmission electron microscopy and dynamic light scattering results showed that these cur-CD-GNPs have a small gold nanocore (approximately 5 nm) and the average size of the three cur-CD-GNPs was approximately 25-35 nm. Curcumin was efficiently incorporated into the ß-CD solution and the loading efficiency of curcumin in ß-CD-GNPs was the highest of the three types of CD-GNPs prepared. The cytotoxic effect of cur-CD-GNPs was investigated using a human lung cancer cell line. All cur-CD-GNPs exhibited cytotoxic effects comparable to that of curcumin solution and CD-GNPs without curcumin were not cytotoxic. These results suggest that cur-CD-GNPs may be a useful multifunctional nanomedicine, although in vivo investigations are required.


Asunto(s)
Antineoplásicos/química , Curcumina/química , Ciclodextrinas/química , Oro/química , Nanopartículas del Metal/química , Polietilenglicoles/química , Células A549 , Antineoplásicos/toxicidad , Transporte Biológico , Supervivencia Celular/efectos de los fármacos , Curcumina/toxicidad , Ciclodextrinas/toxicidad , Composición de Medicamentos , Oro/toxicidad , Humanos , Nanopartículas del Metal/toxicidad , Polietilenglicoles/toxicidad
8.
Biol Pharm Bull ; 40(6): 815-823, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28566625

RESUMEN

The trans platinum-chloroquine diphosphate dichloride (PtCQ) is a new type of antimalarial drug used to fight parasites resistant to traditional drugs. PtCQ is synthesized by mixing platinum and chloroquine diphosphate (CQ). This study examines two efficient methods for forming a nanodrug, PtCQ-loaded liposomes, for use as a potential antimalarial drug-delivery system: the thin drug-lipid film method to incorporate the drug into a liposomal membrane, and a remote-loading method to load the drug into the interior of a cationic liposome. The membranes accordingly comprised PEGylated neutral or cationic liposomes. PtCQ was efficiently loaded into PEGylated neutral and cationic liposomes using the thin drug-lipid film method (encapsulation efficiency, EE: 76.1±6.7% for neutral liposomes, 1 : 14 drug-to-lipid weight ratio; 70.4±9.8% for cationic liposomes, 1 : 14 drug-to-lipid weight ratio). More PtCQ was loaded into PEGylated neutral liposomes using the remote-loading method than by the thin drug-lipid film method and the EE was maximum (96.1±4.5% for neutral liposomes, 1 : 7 (w/w)). PtCQ was encapsulated in PEGylated cationic liposomes comprising various amounts of cationic lipids (0-20 mol%; EE: 96.9-92.3%) using the remote-loading method. PEGylated neutral liposomes and cationic liposomes exhibited minimum leakage of PtCQ after two months' storage at 4°C, and further exhibited little release under in vitro culture conditions at 37°C for 72 h. These results provide a useful framework for the design of future liposome-based in vivo drug delivery systems targeting the malaria parasite.


Asunto(s)
Antimaláricos/química , Cloroquina/análogos & derivados , Sistemas de Liberación de Medicamentos , Platino (Metal)/química , Polietilenglicoles/química , Cloroquina/química , Liberación de Fármacos , Resistencia a Medicamentos , Lípidos/química , Liposomas , Malaria , Plasmodium falciparum
9.
Biol Pharm Bull ; 40(3): 357-364, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28250279

RESUMEN

Three-dimensional (3D) printers have been applied in many fields, including engineering and the medical sciences. In the pharmaceutical field, approval of the first 3D-printed tablet by the U.S. Food and Drug Administration in 2015 has attracted interest in the manufacture of tablets and drugs by 3D printing techniques as a means of delivering tailor-made drugs in the future. In current study, polyvinylalcohol (PVA)-based tablets were prepared using a fused-deposition-modeling-type 3D printer and the effect of 3D printing conditions on tablet production was investigated. Curcumin, a model drug/fluorescent marker, was loaded into PVA-filament. We found that several printing parameters, such as the rate of extruding PVA (flow rate), can affect the formability of the resulting PVA-tablets. The 3D-printing temperature is controlled by heating the print nozzle and was shown to affect the color of the tablets and their curcumin content. PVA-based infilled tablets with different densities were prepared by changing the fill density as a printing parameter. Tablets with lower fill density floated in an aqueous solution and their curcumin content tended to dissolve faster. These findings will be useful in developing drug-loaded PVA-based 3D objects and other polymer-based articles prepared using fused-deposition-modeling-type 3D printers.


Asunto(s)
Excipientes , Alcohol Polivinílico , Impresión Tridimensional , Comprimidos , Curcumina/administración & dosificación , Polímeros , Tecnología Farmacéutica/métodos
10.
Biol Pharm Bull ; 40(2): 145-150, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28154252

RESUMEN

Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular degeneration (AMD) caused by angiogenesis. Ranibizumab has a short half-life in the eye due to its low molecular weight and susceptibility to proteolysis. Monthly intravitreal injection of a large amount of ranibizumab formulation is a burden for both patients and medical staff. We therefore sought to develop a sustainable release system for treating the eye with ranibizumab using a drug carrier. A ranibizumab biosimilar (RB) was incorporated into microparticles of poly(lactic-co-glycolic acid) (PLGA) biodegradable polymer. Ranibizumab was sustainably released from PLGA microparticles (80+% after 3 weeks). Assay of tube formation by endothelial cells indicated that RB released from PLGA microparticles inhibited VEGF-induced tube formation and this tendency was confirmed by a cell proliferation assay. These results indicate that RB-loaded PLGA microparticles are useful for sustainable RB release and suggest the utility of intraocular sustainable release systems for delivering RB site-specifically to AMD patients.


Asunto(s)
Biosimilares Farmacéuticos/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Ácido Láctico/metabolismo , Microesferas , Ácido Poliglicólico/metabolismo , Ranibizumab/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Biosimilares Farmacéuticos/administración & dosificación , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/metabolismo , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/metabolismo , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Ácido Láctico/administración & dosificación , Ácido Poliglicólico/administración & dosificación , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ranibizumab/administración & dosificación , Factor A de Crecimiento Endotelial Vascular/administración & dosificación
11.
Drug Dev Ind Pharm ; 43(5): 715-722, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27401130

RESUMEN

CONTEXT: The development of taste-masking technologies for foods and drugs is essential because it would enable people to consume and receive healthy and therapeutic effect without distress. OBJECTIVE: In the current study, in order to develop a novel method to prepare nanocomposite particles (microparticles containing bitter nanoparticles) in only one step, by using spray drying, a two-solution mixing nozzle-equipped spray dryer that we previously reported was used. The nanocomposite particles with or without poorly water-soluble polymers prepared using our spray-drying technique were characterized. METHODS: (1) The organic solution containing quinine, a model of bitter compound and poorly water-soluble polymers and (2) sugar alcohol (mannitol) aqueous solution were separately flown in tubes and two solutions were spray dried through two-solution type spray nozzle to prepare polymer-blended quinine nanocomposite particles. Mean diameters of nanoparticles, taste-masking effect and dissolution rate of quinine were evaluated. RESULTS: The results of taste masking by taste sensor suggested that the polymer (Eudragit EPO, Eudragit S100 or Ethyl cellulose)-blended quinine nanocomposite particles exhibited marked masking of instrumental quinine bitterness compared with the quinine nanocomposite particles alone. Quinine nanocomposite formulations altered the quinine dissolution rate, indicating that they can control intestinal absorption of quinine. CONCLUSION: These results suggest that polymer-blended quinine composite particles prepared using our spray-drying technique are useful for masking bitter tastes in the field of food and pharmaceutical industry.


Asunto(s)
Nanocompuestos/química , Polímeros/química , Quinina/química , Percepción del Gusto/efectos de los fármacos , Gusto/efectos de los fármacos , Química Farmacéutica/métodos , Desecación/métodos , Manitol/química , Nanopartículas/química , Tamaño de la Partícula , Solubilidad , Soluciones/química , Tecnología Farmacéutica/métodos , Agua/química
12.
Biol Pharm Bull ; 38(10): 1649-51, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26424025

RESUMEN

Malaria is one of the most prevalent parasitic diseases and is most widespread in tropical regions. The malarial parasite grows and reproduces in erythrocytes during its life cycle, resulting in programmed erythrocyte death, termed eryptosis. Lipid scrambling, which occurs following the exposure of anionic lipids such as phosphatidylserine (PS) on the outer surface of erythrocytes, is a characteristic physical change that occurs early during eryptosis. Here, we prepared "PS specific peptide (PSP)"-conjugated liposomes (PSP-liposomes) and investigated whether PSP-liposomes hold promise as a novel strategy for actively targeting eryptosis. Eryptosis was induced by exposing red blood cells (RBCs) to ionomycin, a known calcium ionophore. When PSP liposomes were mixed with either RBCs or RBCs undergoing eryptosis (E-RBCs), the amount of PSP-liposome bound to E-RBCs was much higher than the amount bound to RBCs. However, the amount of PSP-liposome bound to E-RBCs was significantly inhibited by the presence of annexin V protein, which binds specifically to PS. These results suggest that PSP-liposomes could be an effective drug nanocarrier for treating E-RBCs and malaria-infected erythrocytes.


Asunto(s)
Apoptosis/efectos de los fármacos , Eritrocitos/efectos de los fármacos , Lípidos/farmacología , Liposomas/farmacología , Péptidos/farmacología , Animales , Modelos Animales de Enfermedad , Eritrocitos/parasitología , Lípidos/química , Liposomas/química , Malaria , Masculino , Ratones , Péptidos/química , Plasmodium
13.
Int J Pharm ; 648: 123597, 2023 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-37952559

RESUMEN

Eudragit S100-coated bile salt-containing liposomes were prepared and optimized by experimenting with different variables, including bile salt type and concentration, and the method of incorporation into liposomes using a model hydrophilic compound, 5-aminosalicylic acid (5-ASA). After optimizing the formulation, cellular uptake, and animal pharmacokinetic experiments were performed. The inclusion of sodium glycocholate (SG) into liposomes decreased liposome particle size and entrapment efficiency significantly but had no effect on zeta potential. The method of incorporating SG into the lipid or aqueous phase of the liposome did not notably impact the characteristics of the liposomes but the hydration media had a substantial effect on the entrapment efficiency of 5-ASA. In vitro drug release in different fluids simulating distinct gastrointestinal tract sections, indicated pH-dependent disintegration of the coating layer of coated SG-containing liposomes. The majority of the drug was retained when subjected to simulated gastric fluid (SGF) and fed-state simulated intestinal fluid (FeSSIF) (≈ 37% release after 2 h in SGF pH 1.2, followed by 3 h in FeSSIF pH 5). The remaining drug was subsequently released in phosphate-buffered saline pH 7.4 (≈ 85% release within 24 h). Increasing SG concentration in the liposomes decreased the amount of drug released in FeSSIF. Similar results were observed when SG was replaced with sodium taurocholate. Cellular uptake studies in Caco-2 cells demonstrated that all liposomal formulations (conventional liposomes, bile salt-containing liposomes, and coated bile salt-containing liposomes) have shown to be equally effective at increasing the cellular uptake compared to free fluorescein solution. In the pharmacokinetic study, coated bile salt-containing liposomes showed a lower Cmax and prolonged residence in the gastrointestinal tract in comparison to conventional liposomes. Taken together, these findings suggest that the polymer-coated bile salt-containing liposomes have the potential to serve as a drug delivery system targeted at the colon.


Asunto(s)
Liposomas , Mesalamina , Humanos , Animales , Liposomas/química , Mesalamina/metabolismo , Ácidos y Sales Biliares , Células CACO-2 , Ácido Glicocólico/química , Colon/metabolismo
14.
Biol Pharm Bull ; 35(11): 1926-31, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23123464

RESUMEN

Production of drug nanoparticles is an effective strategy to enhance solubility and oral absorption of water-insoluble drugs. The handling of drug nanoparticles has been an important issue in drug formulation because nanoparticles easily aggregate each other and redispersion of these particles is very difficult. In the present study, we developed a unique two-solution mixing type spray nozzle that can prepare drug nanoparticles in microparticles in one step without any common solvent and surfactant, and then, the prepared formulation were evaluated. Ethylcellulose (EC) and mannitol (MAN) were used as a model polymer of water-insoluble compound and a water-soluble carrier, respectively. We characterized the EC/MAN microparticles produced by the novel spray nozzle when customizing the nozzle parts to mix EC and MAN solution. Relatively smaller EC nanoparticles (<110 nm) in MAN microparticles (approximately 3 µm) were obtained by changing the customizable parts in the nozzle. In addition, the core of EC nanoparticles (<50 nm) was also observed by atomic force microscopy. We also found that the mixing time in the nozzle parts affected the size and the standard deviation of EC nanoparticles. These results suggest that the size of EC nanoparticles in MAN microparticles is controllable by using this unique nozzle. After all, we could prepare MAN microparticles containing EC nanoparticles in one step by using the novel nozzle. The drug/MAN microparticles formulation produced by the nozzle may be useful for the handling of drug nanoparticles.


Asunto(s)
Composición de Medicamentos/instrumentación , Nanopartículas , Celulosa/análogos & derivados , Celulosa/química , Composición de Medicamentos/métodos , Diseño de Equipo , Manitol/química , Microscopía Electrónica de Rastreo , Nanopartículas/química , Nanopartículas/ultraestructura , Tamaño de la Partícula , Soluciones
15.
Biol Pharm Bull ; 35(4): 545-50, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22466559

RESUMEN

We have developed a drug-loaded poly(lactic-co-glycolic acid) (PLGA) microsphere-containing thermoreversible gelation polymer (TGP) (drug/PLGA/TGP) formulation as a novel device for implantation after surgical glioma resection. TGP is a thermosensitive polymer that is a gel at body temperature and a sol at room temperature. When a drug/PLGA/TGP formulation is injected into a target site, PLGA microspheres in TGP gel localize at the injection site and do not diffuse across the entire brain tissue, and thus, sustained drug release from the PLGA microspheres at the target site is expected. Using in vivo imaging, we confirmed that the implantation of indocyanine green (ICG)/PLGA/TGP formulation exhibited a stronger localization of ICG at the injection site 28 d after injection compared with that of ICG/PLGA formulation. The therapeutic effect (mean survival) was evaluated in a C6 rat glioma model. Surgical tumor resection alone showed almost no effect on survival (controls, 18 d; surgical resection; 18.5 d). Survival was prolonged after the treatment with a camptothecin (CPT; 10 µg)/PLGA/TGP formulation (24 d). The combination treatment of surgical tumor resection and CPT/PLGA/TGP showed almost the same therapeutic effect (24 d) compared with CPT/PLGA/TGP alone, while the combination treatment produced long term survivors (>60 d). Therefore, the CPT/PLGA/TGP formulation can be an effective candidate for localized and sustained long-term glioma therapy.


Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/cirugía , Camptotecina/administración & dosificación , Glioma/tratamiento farmacológico , Glioma/cirugía , Animales , Línea Celular Tumoral , Terapia Combinada , Portadores de Fármacos/administración & dosificación , Implantes de Medicamentos , Hidrogeles/administración & dosificación , Ácido Láctico/administración & dosificación , Masculino , Microesferas , Ácido Poliglicólico/administración & dosificación , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas , Ratas Sprague-Dawley
16.
Int J Pharm ; 617: 121448, 2022 Apr 05.
Artículo en Inglés | MEDLINE | ID: mdl-35066116

RESUMEN

3D printing technology is a novel and practical approach for producing unique and complex industrial and medical objects. In the pharmaceutical field, the approval of 3D printed tablets by the US Food and Drug Administration has led to other 3D printed drug formulations and dosage forms being proposed and investigated. Here, we report novel ophthalmologic patches for controlled drug release fabricated using a semi-solid material extrusion-type 3D printer. The patch-shaped objects were 3D printed using hydrogel-based printer inks composed of hypromellose (HPMC), sugar alcohols (mannitol, xylitol), and drugs, then freeze-dried. The viscous properties of the printer inks and patches were dependent on the HPMC and sugar alcohol concentrations. Then, the physical properties, surface structure, water uptake, antimicrobial activity, and drug release profile of lyophilized patches were characterized. Lyophilized ophthalmologic patches with different dosages and patterns were fabricated as models of personalized treatments prepared in hospitals. Then, ophthalmologic patches containing multiple drugs were fabricated using commercially available eye drop formulations. The current study indicates that 3D printing is applicable to producing novel dosage forms because its high flexibility allows the preparation of patient-tailored dosages in a clinical setting.


Asunto(s)
Excipientes , Impresión Tridimensional , Composición de Medicamentos , Liberación de Fármacos , Humanos , Derivados de la Hipromelosa/química , Comprimidos , Tecnología Farmacéutica
17.
Yakugaku Zasshi ; 141(3): 323-326, 2021.
Artículo en Japonés | MEDLINE | ID: mdl-33642498

RESUMEN

Nanomedicine is a new medical field involving the use of nanoparticles. Early examples of biocompatible nanomedicines include liposomes (Doxil®) and albumin nanoparticles (Abraxane®), and promising new nanomedicines include nanocarriers such as nanomicelles and nanoemulsions. A new trend towards the use of metal-based nanoparticles, including gold nanoparticles, has led to global clinical trials. These particles exhibit novel properties compared to conventional nanomedicines such as liposomes and albumin nanoparticles. These properties hold promise for nanomedicines, and thus the biodistribution and pharmacokinetics of metal-based nanoparticles should be carefully investigated. This had led to an increasing number of clinical trials investigating metal nanoparticles and inorganic nanoparticles. The present review evaluates multi-functional gold nanoparticles described in recent articles and shows that the unique properties of gold nanoparticles are applicable for not only drug delivery, but also for imaging. The combined therapeutic modality between therapeutics and diagnostics is called "theranostics" and is promising for future personalized cancer therapy. This review also introduces recent research from our laboratory involving the use of various kinds of molecules [polyethylene glycol (PEG), drug/cyclodextrin inclusion complexes, biosimilars and small interfering (siRNAs)] loaded onto and/or conjugated with gold nanoparticles.


Asunto(s)
Sistemas de Liberación de Medicamentos , Oro , Nanopartículas del Metal , Nanomedicina , Nanotecnología , Neoplasias/tratamiento farmacológico , Albúminas , Materiales Biocompatibles , Diagnóstico por Imagen , Oro/farmacocinética , Humanos , Liposomas , Medicina de Precisión
18.
Int J Pharm ; 583: 119338, 2020 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-32311468

RESUMEN

The liposome-protamine-DNA complex (LPD) is an effective cationic carrier of various nucleic acid constructs such as plasmid DNA and small interfering RNA (siRNA). Hyaluronic acid coated on LPD (LPDH) reduces cytotoxicity and maintains the silencing effect of LPD-encapsulated siRNA. Herein, we aim to develop LPD- or LPDH-containing spray-freeze-dried particles (SFDPs) for therapeutic delivery of siRNA to the lungs. LPD- or LPDH-containing SFDPs (LPD- or LPDH-SFDPs) were synthesized and their structure and function as gene carriers were evaluated using physical and biological methods. The particle size of LPDH, but not of LPD, was constant after re-dispersal from the SFDPs and the amount of siRNA encapsulated in LPDH was larger than that in LPD after re-dispersal from the SFDPs. The in vitro pulmonary inhalation properties of LPDH-SFDPs and LPD-SFDPs were almost the same. The cytotoxicity of LPDH-SFDPs in human umbilical vein endothelial cells (HUVEC) was greatly decreased compared with that of LPD-SFDPs. In addition, Bcl-2 siRNA in LPDH-SFDPs had a significant gene silencing effect in human lung cancer cells (A549), whereas Bcl-2 siRNA in LPD-SFDPs had little effect. These results indicate that compared with LPD, LPDH is more useful for developing SFDPs for siRNA pulmonary inhalation.


Asunto(s)
ADN , Ácido Hialurónico , Protaminas , ARN Interferente Pequeño , Células A549 , Administración por Inhalación , Supervivencia Celular/efectos de los fármacos , ADN/administración & dosificación , ADN/química , Liofilización , Silenciador del Gen , Células Endoteliales de la Vena Umbilical Humana/efectos de los fármacos , Humanos , Ácido Hialurónico/administración & dosificación , Ácido Hialurónico/química , Liposomas , Protaminas/administración & dosificación , Protaminas/química , Proteínas Proto-Oncogénicas c-bcl-2/genética , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/química
19.
Int J Pharm ; 568: 118494, 2019 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-31276763

RESUMEN

3D printing technology holds promise for application to personalized pharmaceuticals. Mold fabrication is a common technique in industrial 3D printing to produce objects with complex structures and could be used in new applications in pharmaceutical production. The aim of the current study is the fabrication of unique suppository shell molds composed of a water-soluble polymer (polyvinylalcohol) using a fused deposition modeling-type 3D printer so that hospital pharmacists can prepare tailored suppository formulations containing progesterone (a model drug for vaginal suppository formulations) in future clinical settings. Suppository formulations with holes in the shells were prepared. The drug release profiles related well to the positions of the holes (upper, middle, lower), the number of holes (0-2 holes), and the diameters of the holes (0-5 mm) in the suppositories. Matryoshka-type suppository formulations composed of 3D-printed multilayered shells were then prepared. The drug release profiles showed pulsed release, and the volumes of the inner/outer spaces in the suppository shells (1/1, 1/3) and the drug concentration (3/1, 1/1) were reflected in the observed drug release profiles. Our study indicates that a 3D printer can produce not only unique and complex suppository formulations, but also provides flexibility and expands possible applications for the development of tailored medicine.


Asunto(s)
Impresión Tridimensional , Supositorios/química , Preparaciones de Acción Retardada/química , Liberación de Fármacos , Polietilenglicoles/química , Polímeros/química , Alcohol Polivinílico/química , Progesterona/química , Solubilidad , Agua/química
20.
J Pharm Sci ; 108(2): 907-913, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30267782

RESUMEN

The production of three-dimensional (3D)-printed drugs holds promise for future personalized medicine. Here, we prepared tablets containing naftopidil as a model drug using a semisolid extrusion-type 3D bioprinter applicable for tissue engineering. A hydrogel is typically used as the printer ink for 3D bioprinters, and we incorporated various amounts of hydroxypropyl methylcellulose hydrogel (30%, 40%, and 50% gel) into the printer ink. The resulting 3D-printed gel product was dried to obtain tablets. The rheological properties of the printer ink changed as its composition was changed, and tablets were prepared successfully from several formulations. Increasing the amount of hydroxypropyl methylcellulose hydrogel in the printer ink led to delayed drug dissolution, decreased weight, and decreased hardness of the tablets. Delayed drug dissolution was also observed when the amount of disintegrating agent typically used in powder compression tablets was increased in the ink, and increasing the incorporated amount of the disintegrating agent crospovidone increased the hardness of the tablets. Our results will provide useful information for the preparation of tablets using semisolid extrusion-type 3D printers.


Asunto(s)
Antagonistas Adrenérgicos alfa/administración & dosificación , Preparaciones de Acción Retardada/química , Hidrogeles/química , Derivados de la Hipromelosa/química , Naftalenos/administración & dosificación , Piperazinas/administración & dosificación , Antagonistas Adrenérgicos alfa/química , Composición de Medicamentos , Liberación de Fármacos , Excipientes/química , Naftalenos/química , Piperazinas/química , Povidona/química , Impresión Tridimensional , Comprimidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA